WASF2 and prostate cancer: Among these 11 DGs, SLC7A11 can affect non-small cell lung cancer (31), renal cell carcinoma (32), prostate cancer progression through ferroptosis, and WASF2 is associated with poor ovarian cancer prognosis (33).